Fig. 1

Mortaparib targets mortalin and results in growth arrest in HeLa cells. Control and Mortaprib-treated cells were analyzed for the expression level of mortalin and p53 by Western blotting (a), immunostaining (b) and RT-PCR (c). Decrease in mortalin and increase in p53 levels was marked in all assays. p53-specific luciferease reporter assays using either p53-binding consensus sequence or p21-promoter (~ 2.8 kb) showed increase in p53-driven luciferase in Mortaparib-treated HeLa as well as U2OS cells (d). Mortaparib-treated cells showed increase in p21 by immunostaining (e). Western blot analysis showed increase in p21 and decrease in CDK4, Cyclin D1, pRb and E2F1. Quantitation is shown on the right (f). Cell cycle analysis showed increase in number of HeLa cells in S phase upon Mortaparib treatment (g). The quantitative data represents mean ± SD obtained from, at least, three independent experiments; p-values were calculated using Student’s t-test. * < 0.05, ** < 0.01 and *** < 0.001 represent significant, very significant and very very significant, respectively. Scale bar in B and E = 20 μM